1. Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma
- Author
-
Anthony W.H. Chan, Junhong Zhao, Yujuan Dong, Saifung Yeung, Frankie M.C. Sin, Wei Kang, Shiyan Wang, Alfred S. L. Cheng, Jun Yu, Ka Fai To, and Joanna H.M. Tong
- Subjects
Cancer Research ,Small interfering RNA ,Ribonucleoside Diphosphate Reductase ,Adenocarcinoma ,Biology ,medicine.disease_cause ,Mice ,Downregulation and upregulation ,Stomach Neoplasms ,Cell Line, Tumor ,medicine ,Animals ,Humans ,RNA, Small Interfering ,Cell Proliferation ,Cell growth ,Cancer ,General Medicine ,Cell cycle ,medicine.disease ,Xenograft Model Antitumor Assays ,Molecular biology ,Gene Expression Regulation, Neoplastic ,Ribonucleotide reductase ,Oncology ,Tumor progression ,Carcinogenesis - Abstract
Ribonucleotide reductase M2 subunit (RRM2) is one of the two subunits of human ribonucleotide reductase which plays a critical role in tumor progression. The aim of the present study was to analyze its expression, clinical significance and biological functions in gastric adenocarcinoma. We observed the upregulation of RRM2 mRNA and protein in all nine gastric cancer cell lines examined. In paired primary gastric cancers, both mRNA and protein levels of RRM2 were significantly upregulated in tumors compared with the corresponding non-tumorous gastric tissues. RRM2 protein expression correlated with higher tumor grade, advanced T stage and poor disease-specific survival. RRM2 knockdown in gastric cancer cell lines AGS, MKN1 and MKN28 significantly suppressed cell proliferation, inhibited monolayer colony formation, reduced cell invasion and induced apoptosis. Downregulation of RRM2 suppressed xenograft formation in vivo. Collectively, these findings suggest that RRM2 plays a crucial role in gastric tumorigenesis and may serve as a potential prognostic marker and therapeutic target in gastric cancer.
- Published
- 2014
- Full Text
- View/download PDF